ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0050

Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice

Sung Hae Chang1, Jeongjun Choe2, Seon Uk Kim3, Jeong Yeon Kim4, Sung Won Lee5, Jeong Seok Lee6 and Eun Young Lee4, 1Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, 2Sungkyunkwan University, Seoul, Republic of Korea, 3Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, 4Seoul National University College of Medicine, Seoul, Republic of Korea, 5Sooncheonhyang University College of Medicine, Seoul, Republic of Korea, 6Korea Advanced Institute of Science and Technology, KAIST, Graduate school of Medical Science and Engineering, Daejeon, Republic of Korea

Meeting: ACR Convergence 2022

Keywords: Animal Model, Disease-Modifying Antirheumatic Drugs (Dmards), genomics, interstitial lung disease, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Animal Models Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the pivotal extrapulmonary conditions. However, the pathophysiology of RA-ILD, including the effect of disease-modifying anti-rheumatoid drugs (DMARDs) is largely unknown. To study the effect of methotrexate and TNFα inhibitor on lung microenvironment of SKG mice using single-nucleus RNA sequencing.

Methods: Male SKG mice of eight to ten weeks received a single intraperitoneal zymosan A (ZyA) injection to induce arthritis and pneumonitis. We gave them twice-weekly intraperitoneal injections of PBS, methotrexate (7.5 mg/kg; MilliporeSigma), or TNFα inhibitor (100 μg/kg; R&D Systems, Inc., Minneapolis, MN, USA). Nuclei were prepared from frozen lung tissue under ribonuclease-free conditions by a method adapted from an existing protocol.

Results: Macroscopically, pneumonitis was most evident in SKG mice with ZyA and methotrexate treatment. A total of 59,860 nuclei were obtained from sixteen mice, four mice from each of the four groups. We classified each cell type using previous reports on the single-nucleus cells of mouse lungs. The most frequently observed cell was the type 2 alveolar (AT2) cell among all four groups. Alveolar epithelial cells were further subclustered into six clusters. Cluster 2 highly expressed type 1 alveolar (AT1) cell marker genes. Interestingly, a distinct cluster 3 was observed after methotrexate treatment. This distinctive alveolar epithelial cell cluster (cluster 3) showed IL-1, TNF, IFNα, and IFNγ perturbation-response signatures using Library of Integrated Network-Based Cellular Signatures (LINCS) 1000 ligand perturbation analysis. In addition, enrichment analysis revealed that cluster 3, as well as cluster 2 (i.e., AT1 cells) significantly enriched genes of BMI1 knockout mice that fail to self-renew their lung cells after damage.

Conclusion: The current study shows that methotrexate exacerbates lung inflammation via attenuation of the regenerative potential of AT2 cells.

Supporting image 1


Disclosures: S. Chang, None; J. Choe, None; S. Kim, None; J. Kim, None; S. Lee, None; J. Lee, None; E. Lee, None.

To cite this abstract in AMA style:

Chang S, Choe J, Kim S, Kim J, Lee S, Lee J, Lee E. Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/effect-of-disease-modifying-anti-rheumatic-drugs-on-lung-microenvironment-of-skg-mice/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-disease-modifying-anti-rheumatic-drugs-on-lung-microenvironment-of-skg-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology